News & Updates

Show Multimedia Only

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025 by

The third-generation human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugate (ADC) SHR-A1811 has passed its phase II trial, demonstrating safety and efficacy in the neoadjuvant setting for patients with HER2-positive breast cancer.

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025

$CAR T-cell therapy offers survival benefits in refractory B-cell ALL$

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

12 Jun 2025

Chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) demonstrates efficacy with high rates of durable remissions, as shown in a recent meta-analysis.

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

12 Jun 2025

Simvastatin confers no additional antidepressant benefit when added to escitalopram

12 Jun 2025

In patients with comorbid major depressive disorder (MDD) and obesity, adding simvastatin to escitalopram does not appear to produce additional antidepressive effects despite improving the cardiovascular risk profile, according to a study.

Simvastatin confers no additional antidepressant benefit when added to escitalopram

12 Jun 2025

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

11 Jun 2025

The addition of granulocyte colony-stimulating factor (GCSF) to prednisolone results in improved steroid responsiveness and prolonged survival with fewer infections and new-onset complications among patients with severe alcohol-associated hepatitis (SAH), a study has shown.

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

11 Jun 2025

Fewer migraine days with zonisamide in children

11 Jun 2025 by

A retrospective cohort study presented at AAN 2025 has demonstrated that prophylactic zonisamide can significantly reduce headache days per month (HDPM) in paediatric patients with migraine.

Fewer migraine days with zonisamide in children

11 Jun 2025

V-ERAT trumps antibiotics for uncomplicated acute appendicitis

10 Jun 2025

Patients with uncomplicated acute appendicitis may opt for visual endoscopic retrograde appendicitis therapy (V-ERAT) as a safe and effective alternative to antibiotic treatment to reduce the risk of recurrence, according to a study.

V-ERAT trumps antibiotics for uncomplicated acute appendicitis

10 Jun 2025

Is social media a reliable source of paediatric drug information?

10 Jun 2025 by

Using social media to obtain relevant information is possible, with a recent study suggesting that data from child-rearing public parenting forums (CPPFs) may aid in assessing paediatric adverse drug events and in detecting unknown adverse drug reactions (ADRs) and medication errors.

Is social media a reliable source of paediatric drug information?

10 Jun 2025

Are statins protective against HCC?

10 Jun 2025 by

In a study presented at EASL 2025, the use of statins appears to be associated with a reduced risk of hepatocellular carcinoma (HCC) and slower progression of liver fibrosis in individuals with chronic liver disease (CLD).

Are statins protective against HCC?

10 Jun 2025

Efruxifermin misses mark in MASH-related compensated cirrhosis

10 Jun 2025

Treatment with the bivalent fibroblast growth factor 21 (FGF21) analogue efruxifermin falls short of improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction–associated steatohepatitis (MASH), according to a phase 2b study.

Efruxifermin misses mark in MASH-related compensated cirrhosis

10 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

SHR-A1811 shows promise vs HER2-positive breast cancer

SHR-A1811 shows promise vs HER2-positive breast cancer

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

Simvastatin confers no additional antidepressant benefit when added to escitalopram

Simvastatin confers no additional antidepressant benefit when added to escitalopram

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

Fewer migraine days with zonisamide in children

Fewer migraine days with zonisamide in children

V-ERAT trumps antibiotics for uncomplicated acute appendicitis

V-ERAT trumps antibiotics for uncomplicated acute appendicitis

Is social media a reliable source of paediatric drug information?

Is social media a reliable source of paediatric drug information?

Are statins protective against HCC?

Are statins protective against HCC?

Efruxifermin misses mark in MASH-related compensated cirrhosis

Efruxifermin misses mark in MASH-related compensated cirrhosis